Risk factors for charcot foot.

• Autor(a) principal: NÓBREGA, M. B. DE M.
• Data de Publicação: 2015
• Outros Autores: ARAS, R., MARTINS NETTO, E., COUTO, R. D., MARINHO, A. M. DA N., SILVA FILHO, J. L. da, COLARES, V. N. Q., CAMPELO, P. L., NUNES, M. A. L.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da EMBRAPA (Repository Open Access to Scientific Information from EMBRAPA - Alice)
• Texto Completo: http://www.alice.cnptia.embrapa.br/alice/handle/doc/1041258
• topic: Charcot foot; Charcot neuroarthropathy; Diabete; diabetes mellitus; diabetic neuropathy

Objective: Diabetes mellitus is the main cause of Charcot neuroarthropathy and is clinically classified as follows: Charcot foot, acute Charcot foot (ACF) when there is inflammation, and inactive Charcot foot when inflammatory signs are absent. The aim of this study was to identify the risk factors for ACF in patients with type 2 diabetes mellitus. Materials and methods: A matched case-control study was conducted to assess the factors associated with acute Charcot foot from February 2000 until September 2012. Four controls for each case were selected 47 cases of ACF and 188 controls without ACF were included. Cases and controls were matched by year of initialization of treatment. Conditional logistic regression was used to estimate matched odds ratios (ORs) and 95% confidence intervals (95% CIs). Results: In multivariate analysis, patients having less than 55 years of age (adjusted OR = 4.10, 95% CI = 1.69 ? 9.94), literate education age (adjusted OR = 3.73, 95% CI = 1.40 ? 9.92), living alone (adjusted OR = 5.84, 95% CI = 1.49 ? 22.86), previous ulceration (adjusted OR = 4.84, 95% CI = 1.62 ? 14.51) were at increased risk of ACF. However, peripheral arterial disease (adjusted OR = 0.16, 95% CI = 0.05 ? 0.52) of 6.25 (1.92 ? 20.0) was a protective factor. Discussion: The results suggest that PCA in type 2 diabetes primarily affects patients under 55 who live alone, are literate, and have a prior history of ulcers, and that peripheral arterial disease is a protective factor. Arch Endocrinol Metab. 2015;59(3):226-30.